October 05, 2016 – Here, we make available to our readers a Drug Safety Communication by the American Food & Drug Administration (FDA), where FDA warns about the risk of hepatitis B virus (HBV) reactivation in some patients treated with …

FDA warns about the risk of HBV reactivation in patients treated with DAA for HCV-infection Read more »

June 29, 2016 – The saga goes on: The American  Food & Drug Administration (FDA) just approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) infection both with and without cirrhosis (advanced liver disease). For patients with …

The HCV saga goes on: Epclusa has been approved for treatment of chronic Hepatitis C virus (HCV) infection Read more »

May 30, 2016 – According to its News and Events section of the homepage, the European Medicines Agency (EMA) has recommended the granting of marketing authorisations in the European Union (EU) for two new combination therapies against chronic (long-term) hepatitis C virus (HCV) infection, namely …

EMA: Two new combination therapies against chronic hepatitis C recommended for approval Read more »